Last Update 18 Feb 26

Fair value Decreased 0.61%

IDXX: New Diagnostics Pipeline And Margin Outlook Will Support Future Shareholder Value

The analyst price target for IDEXX Laboratories has been trimmed by about $4.60 as analysts factor in slightly more measured revenue growth assumptions, a modestly lower future P/E multiple, and a somewhat higher expected profit margin.

Analyst Commentary

Recent Street research has clustered around lower price targets for IDEXX Laboratories, with cuts of about US$20 to US$50 in quick succession. While the headline direction is similar, the rationale behind these moves highlights both optimistic and cautious views on execution and valuation.

Bullish Takeaways

Bullish analysts appear to see room for IDEXX to defend or improve margins, which helps support a still premium P/E even after the target trims.
Price target reductions in the US$20 to US$50 range suggest these analysts continue to see value in the long term story, rather than a fundamental reset of the business model.
The clustering of revisions over a short period can indicate analysts are updating models to reflect more measured assumptions, not abandoning growth expectations altogether.
Some bullish views implicitly assume IDEXX can execute on cost control and mix, which would help offset more conservative top line assumptions in valuation models.

Bearish Takeaways

Bearish analysts are building in more cautious revenue trajectories, which compresses target prices even if the underlying business remains profitable.
The cuts of US$20, US$25, US$30 and US$50 point to less willingness to underwrite the previous P/E levels, suggesting investors may scrutinize every quarter more closely.
Lower targets signal that execution risk around hitting prior growth expectations is top of mind, especially if end market demand or pricing proves slower than previously modeled.
With multiple firms revising targets in quick succession, bearish analysts may see a higher bar for upside surprises relative to the current valuation, making them more guarded on near term risk and reward.

What's in the News

New 2026 outlook calls for revenue in a range of US$4.63b to US$4.72b, with organic growth guidance of 7.0% to 9.0% and projected EPS of US$14.29 to US$14.80, framed around contributions from CAG Diagnostics recurring revenue (Corporate guidance)
Expansion of the IDEXX Cancer Dx Panel to include canine mast cell tumor detection from mid 2026 in North America, with mast cell testing added at no additional cost and positioned to cover over one third of canine cancer cases alongside the existing lymphoma test used by more than 5,500 practices (Product announcement)
Rollout of FNA cytology on the IDEXX inVue Dx Cellular Analyzer starting late fourth quarter 2025, allowing in clinic evaluation of skin masses and optional pathologist review without slide preparation, with plans to extend beyond mast cell tumors over time (Product announcement)
Launch of the ImageVue DR50 Plus Digital Imaging System in the United States and Canada, combining high definition, AI supported imaging with lower radiation doses compared with prior IDEXX and other veterinary imaging systems and integration with IDEXX Web PACS software and telemedicine tools (Product announcement)
Promotion of Michael Erickson, PhD, to CEO effective May 12, 2026, with current CEO Jonathan Mazelsky transitioning to Executive Chair until his planned retirement after the May 2027 shareholder meeting, signaling an extended handover period (Executive change)

Valuation Changes

Fair Value was trimmed slightly from $754.83 to $750.23, keeping the modeled outcome close to prior levels.
The Discount Rate was adjusted marginally from 7.74% to 7.69%, reflecting a small tweak to the risk assumption used in the model.
Revenue Growth is now modeled at 9.01% instead of 9.20%, building in a slightly more measured top line outlook.
The Net Profit Margin was raised from 25.48% to 26.16%, assuming a modest improvement in profitability even with more conservative revenue growth.
The Future P/E was reduced from 51.22x to 50.11x, indicating a small reset in the premium multiple applied to the shares.

2 views

Key Takeaways

Expansion in innovative diagnostic platforms and international markets is driving recurring revenue growth, margin expansion, and enhanced geographic diversification.
Strong customer retention and broader adoption of cloud solutions create stable, high-margin revenue streams and position the company for sustained long-term earnings growth.
Slowing U.S. clinical visit growth, international adoption challenges, reliance on instrument placements, rising competition, and price sensitivity all threaten IDEXX's long-term revenue and margin prospects.

Catalysts

About IDEXX Laboratories

Develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.
Expansion of commercial investments in underpenetrated international markets-combined with localization strategies and tailored product offerings-is fueling double-digit recurring diagnostic revenue growth outside North America, providing geographic diversification and supporting long-term top-line growth.
Increasing utilization rates of advanced diagnostics per clinical visit, supported by pet owners' willingness to spend on preventive and early detection care for an aging pet population, are driving higher diagnostic frequency and supporting recurring revenue and net margin expansion.
Broader adoption and enhancement of cloud-based practice management and analytics solutions is strengthening customer retention, raising multi-product utilization, and increasing customer lifetime value, translating to improved recurring revenue and net margins.
High customer retention and growing installed base of premium instruments provide IDEXX with stable, high-margin recurring revenue streams, positioning the company to compound earnings growth over time as industry consolidation and elevated care standards continue.

IDEXX Laboratories Earnings and Revenue Growth

IDEXX Laboratories Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming IDEXX Laboratories's revenue will grow by 8.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 24.4% today to 25.3% in 3 years time.
Analysts expect earnings to reach $1.3 billion (and earnings per share of $16.93) by about September 2028, up from $985.7 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 48.5x on those 2028 earnings, down from 53.2x today. This future PE is greater than the current PE for the US Medical Equipment industry at 29.7x.
Analysts expect the number of shares outstanding to decline by 2.3% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.44%, as per the Simply Wall St company report.

IDEXX Laboratories Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Sustained declines in U.S. clinical visit growth (down 2.5% in the quarter and forecasted to remain soft) suggest that underlying veterinary visit frequency is under pressure and could limit CAG Diagnostic recurring revenue growth over the long term, directly impacting revenue and earnings resilience.
International markets, while delivering strong growth now, are described as "more embryonic" and dependent on expanding diagnostic use among smaller clinics; slower adoption or inability to replicate U.S.-style diagnostic penetration may temper future global revenue expansion and earnings diversification.
The consumables revenue surge is highly linked to rapid instrument placements (notably inVue Dx); if future instrument placement growth slows or installed base saturation is reached (implied by management's expectation of a relative slowdown in 2H placements compared to 2Q), recurring consumable revenue growth and margin improvements could decelerate, affecting long-term net margins.
Intensifying competition, including from new entrants and disruptive startups targeting point-of-care and specialty diagnostics, is acknowledged as ongoing; any failure to maintain IDEXX's innovation pace or if competitors introduce faster/cheaper solutions could erode pricing power and market share, negatively impacting both revenue growth and net margins.
Heavy reliance on price increases for recent revenue gains (e.g., 4%+ global net price realization), combined with macroeconomic pressures, regulatory risk, and the possibility of large veterinarian groups negotiating lower prices, could squeeze long-term operating margins and restrict IDEXX's ability to sustain high earnings growth rates.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $695.091 for IDEXX Laboratories based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $785.0, and the most bearish reporting a price target of just $420.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $5.2 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 48.5x, assuming you use a discount rate of 7.4%.
Given the current share price of $655.6, the analyst price target of $695.09 is 5.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on IDEXX Laboratories?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

IDXX: Expanding Installed Base Will Drive Accelerating Business Momentum Ahead